期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Canagliflozin：治疗2型糖尿病的新型钠-葡萄糖共转运体2抑制剂 被引量：3

Canagliflozin:a new sodium glucose co-transporter 2 inhibitor in treatment of type 2 diabetes
原文传递
导出
摘要 钠-葡萄糖共转运体2(SGLT2)是近年来新发现的2型糖尿病治疗靶点。抑制SGLT2可减少肾脏葡萄糖的重吸收,增加尿糖排出,从而降低血糖。Canagliflozin是SGLT2抑制剂,可结合饮食控制和运动来改善成人2型糖尿病的血糖。Canagliflozin的推荐剂量为100 mg,口服,每日1次。临床试验表明canagliflozin治疗2型糖尿病安全有效,耐受性好。 Sodium glucose co- transporter 2 （SGLT2） is a newly discovered therapeutic target for the and exercise to improve glycemic control in adults with type 2 diabetes. The recommended dose of canagliflozin is 100 mg orally, once a day. Clinical trials indicated that canagliflozin was effective, safe and tolerated in treating type 2 diabetes.
作者 陈芬燕 张毕奎
机构地区 中南大学药学院 中南大学湘雅三医院药剂科
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第2期86-89,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 湖南省自然科学基金项目(2009SK3003)
关键词 canagliflozin 钠-葡萄糖转运蛋白类 糖尿病 2型 钠-葡萄糖共转运体2抑制剂 canagliflozin sodium-glucose transport proteins diabetes mellitus, type 2 sodium glucose co-transporter 2 inhibitor
分类号 R977 [医药卫生—药品]
  • 相关文献

同被引文献41

  • 1DANAEI G, FINUCANE MM, LU Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet, 2011, 378(9785): 31-40.
  • 2TAHRANI AA, BAILEY C J, del PRATO S, et al. Management of type 2 diabetes: new and future developments in treatment[J]. Lancet, 2011, 378(9786): 182-197.
  • 3COOK MN, GIRMAN C J, STEIN PP, et al. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glyeaemic goals in patients with Type 2 diabetes in UK primary care[J]. Diabet Med, 2007, 24(4) : 350-358.
  • 4LAMOS EM, YOUNK LM, DAVIS SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus [J]. Expert Opin Drug Metab Toxicol, 2013, 9(6): 763-775.
  • 5HIGGINS JPT, GREEN S. Cochrane handbook for systematic reviews of intervention[,EB/OL]. (2011-03 )[2014-10-28]. http :// handbook.cochrane.org/.
  • 6LAVALLE-GONZ/tLEZ F J, JANUSZEWICZ A, DAVIDSON J, et al. Efficacy and safety of canagliflozin compared with placebo and sitaiptin in patients with type 2 diabetes on background mefformin monotherapy: a randomised trial[J]. Diabetologia, 2013, 56(12):2582-2592.
  • 7ROSENSTOCK J, AGGARWAL N, POLIDORI D, et al. Dose- ranging effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add- on to metformin in subjects with type 2 diabetes[J]. Diabetes Care, 2012, 35(6) : 1232-1238.
  • 8SCHERNTHANER G, GROSS JL, ROSENSTOCK J, et ol. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52- week randomized trial [J]. Diabetes Care, 2013, 36(9): 2508-2515.
  • 9CEFALU WT, LEITER LA, YOON KH, et al. Efficacy and safety of canagliflozln versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA- SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial[J]. Lancet, 2013, 382(9896) : 941-950.
  • 10International diabetes Federation (2005). Global Guidelines for type 2 diabetes[EB/OL].(2005)[2014-10-28], http://www.idf.org/ webdat a/docs/GGT2D%2009%20Oral%20therapy .pdf.

引证文献3

二级引证文献8

中国新药与临床杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部